Ambrisentan: A guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

[1] Galie N., Hoper M.M., Humbert M., Et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur Heart J, 30, 20, pp. 2493-537, (2009)

[2] Safdar Z., Targeted oral therapies in the treatment of pulmonary arterial hypertension, Clin Drug Investig, 30, 12, pp. 811-26, (2010)

[3] Galie N., Badesch D., Oudiz R., Et al., Ambrisentan therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 46, 3, pp. 529-35, (2005)

[4] Galie N., Olschewski H., Oudiz R.J., Et al., Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2, Circulation, 117, 23, pp. 3010-9, (2008)

[5] Ghofrani H.-A., Schermuly R., Weissmann N., Et al., Drug interactions in pulmonary arterial hypertension and their implications, US Cardiol, 6, 2, pp. 101-6, (2009)

[6] Spence R., Mandagere A., Richards D.B., Et al., Potential for pharma-cokinetic interactions between ambrisentan and cyclosporine, Clin Pharmacol Ther, 88, 4, pp. 513-20, (2010)

[7] Richards D.B., Spence R., Mandagere A., Et al., Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers, J Clin Pharmacol

[8] Richards D.B., Walker G.A., Mandagere A., Et al., Effect of ketoconazole on the pharmacokinetic profile of ambrisentan, J Clin Pharmacol, 49, 6, pp. 719-24, (2009)

[9] Mandagere A., Coar B., Bird S.W., Et al., Absence of a clinically relevant pharmacokinetic interaction between ambrisentan and mycophenolate mofetil [abstract], Am J Respir Crit Care Med, 181, (2010)

[10] Spence R., Mandagere A., Walker G., Et al., Effect of steady-state am-brisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: An open-label single-sequence single-centre study, Clin Drug Investig, 30, 5, pp. 313-24, (2010)

[1] Galie N., Hoper M.M., Humbert M., Et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur Heart J, 30, 20, pp. 2493-537, (2009)

[2] Safdar Z., Targeted oral therapies in the treatment of pulmonary arterial hypertension, Clin Drug Investig, 30, 12, pp. 811-26, (2010)

[3] Galie N., Badesch D., Oudiz R., Et al., Ambrisentan therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 46, 3, pp. 529-35, (2005)

[4] Galie N., Olschewski H., Oudiz R.J., Et al., Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2, Circulation, 117, 23, pp. 3010-9, (2008)

[5] Ghofrani H.-A., Schermuly R., Weissmann N., Et al., Drug interactions in pulmonary arterial hypertension and their implications, US Cardiol, 6, 2, pp. 101-6, (2009)

[6] Spence R., Mandagere A., Richards D.B., Et al., Potential for pharma-cokinetic interactions between ambrisentan and cyclosporine, Clin Pharmacol Ther, 88, 4, pp. 513-20, (2010)

[7] Richards D.B., Spence R., Mandagere A., Et al., Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers, J Clin Pharmacol

[8] Richards D.B., Walker G.A., Mandagere A., Et al., Effect of ketoconazole on the pharmacokinetic profile of ambrisentan, J Clin Pharmacol, 49, 6, pp. 719-24, (2009)

[9] Mandagere A., Coar B., Bird S.W., Et al., Absence of a clinically relevant pharmacokinetic interaction between ambrisentan and mycophenolate mofetil [abstract], Am J Respir Crit Care Med, 181, (2010)

[10] Spence R., Mandagere A., Walker G., Et al., Effect of steady-state am-brisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: An open-label single-sequence single-centre study, Clin Drug Investig, 30, 5, pp. 313-24, (2010)